Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol.

ABSTRACT:

Introduction

Patients with breast cancer with homologous recombination deficiency (HRD) such as germline BRCA1/2 mutations would respond to DNA-damaging drugs. Several clinical studies have revealed that HRD biomarkers were associated with the outcomes of patients with early breast cancer (EBC). However, no systematic review has determined the prognostic role of HRD biomarkers in patients with EBC. Therefore, this study will systematically combine and analyse the results of previous studies, to facilitate the clinical use of HRD detection in EBC.

Methods and analysis

We will search five databases including PubMed, Cochrane Library, EMBASE, OVID and Web of Science through December 2021, with no language restriction. Two reviewers will independently screen all records based on

SUBMITTER: Liao H 

PROVIDER: S-EPMC9394194 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature